ES3029607T1 - 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 - Google Patents
2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 Download PDFInfo
- Publication number
- ES3029607T1 ES3029607T1 ES21786169T ES21786169T ES3029607T1 ES 3029607 T1 ES3029607 T1 ES 3029607T1 ES 21786169 T ES21786169 T ES 21786169T ES 21786169 T ES21786169 T ES 21786169T ES 3029607 T1 ES3029607 T1 ES 3029607T1
- Authority
- ES
- Spain
- Prior art keywords
- pyrazol
- group
- benzoate
- fluoro
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382861.1A EP3978487A1 (en) | 2020-09-30 | 2020-09-30 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| PCT/EP2021/076730 WO2022069509A1 (en) | 2020-09-30 | 2021-09-29 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3029607T1 true ES3029607T1 (en) | 2025-06-24 |
Family
ID=72744716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21786169T Pending ES3029607T1 (en) | 2020-09-30 | 2021-09-29 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12577230B2 (https=) |
| EP (2) | EP3978487A1 (https=) |
| JP (1) | JP7752684B2 (https=) |
| KR (1) | KR20230079027A (https=) |
| CN (1) | CN116323601A (https=) |
| AR (1) | AR123543A1 (https=) |
| AU (1) | AU2021353965A1 (https=) |
| BR (1) | BR112023004612A2 (https=) |
| CA (1) | CA3196108A1 (https=) |
| ES (1) | ES3029607T1 (https=) |
| IL (1) | IL301663B1 (https=) |
| MX (1) | MX2023002900A (https=) |
| PH (1) | PH12023550777A1 (https=) |
| WO (1) | WO2022069509A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021105317A1 (en) | 2019-11-28 | 2021-06-03 | Origo Biopharma, S.L. | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| WO2026017797A1 (en) | 2024-07-17 | 2026-01-22 | Agomab Spain S.L.U. | Crystalline forms |
| WO2026082960A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | 1,5-naphtyridine and quinoline based inhibitors of alk5 |
| WO2026082968A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | Novel compounds |
| CN121554469B (zh) * | 2026-01-23 | 2026-04-17 | 四川大学华西医院 | 一种alk5 protac化合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| AU754830C (en) * | 1997-05-22 | 2004-02-12 | G.D. Searle Llc | Substituted pyrazoles as p38 kinase inhibitors |
| ATE291020T1 (de) * | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| CA2496295C (en) | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
| WO2004026302A1 (en) | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| WO2007005951A2 (en) * | 2005-07-05 | 2007-01-11 | Aryx Therapeutics, Inc. | Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| CA2720343A1 (en) * | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
| AU2012281281B2 (en) * | 2011-07-13 | 2017-06-01 | Tiumbio Co., Ltd | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| US20210002265A1 (en) | 2018-03-02 | 2021-01-07 | Université de Lausanne | Pyrazole derivatives as inhibitors of the wnt signalling pathway |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| CN110433164A (zh) | 2019-08-15 | 2019-11-12 | 南开大学 | TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用 |
| WO2021105317A1 (en) | 2019-11-28 | 2021-06-03 | Origo Biopharma, S.L. | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
-
2020
- 2020-09-30 EP EP20382861.1A patent/EP3978487A1/en not_active Withdrawn
-
2021
- 2021-09-17 AR ARP210102591A patent/AR123543A1/es unknown
- 2021-09-29 BR BR112023004612A patent/BR112023004612A2/pt unknown
- 2021-09-29 PH PH1/2023/550777A patent/PH12023550777A1/en unknown
- 2021-09-29 ES ES21786169T patent/ES3029607T1/es active Pending
- 2021-09-29 CN CN202180066883.4A patent/CN116323601A/zh active Pending
- 2021-09-29 MX MX2023002900A patent/MX2023002900A/es unknown
- 2021-09-29 IL IL301663A patent/IL301663B1/en unknown
- 2021-09-29 WO PCT/EP2021/076730 patent/WO2022069509A1/en not_active Ceased
- 2021-09-29 CA CA3196108A patent/CA3196108A1/en active Pending
- 2021-09-29 AU AU2021353965A patent/AU2021353965A1/en active Pending
- 2021-09-29 KR KR1020237008242A patent/KR20230079027A/ko active Pending
- 2021-09-29 EP EP21786169.9A patent/EP4222149B1/en active Active
- 2021-09-29 US US18/246,903 patent/US12577230B2/en active Active
- 2021-09-29 JP JP2023519608A patent/JP7752684B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR123543A1 (es) | 2022-12-14 |
| CA3196108A1 (en) | 2022-04-07 |
| IL301663B1 (en) | 2026-01-01 |
| JP7752684B2 (ja) | 2025-10-10 |
| AU2021353965A9 (en) | 2024-08-01 |
| EP4222149A1 (en) | 2023-08-09 |
| US12577230B2 (en) | 2026-03-17 |
| BR112023004612A2 (pt) | 2023-04-11 |
| US20230373966A1 (en) | 2023-11-23 |
| EP4222149B1 (en) | 2026-05-06 |
| IL301663A (en) | 2023-05-01 |
| KR20230079027A (ko) | 2023-06-05 |
| JP2023544716A (ja) | 2023-10-25 |
| CN116323601A (zh) | 2023-06-23 |
| AU2021353965A1 (en) | 2023-04-27 |
| MX2023002900A (es) | 2023-05-25 |
| WO2022069509A1 (en) | 2022-04-07 |
| EP3978487A1 (en) | 2022-04-06 |
| PH12023550777A1 (en) | 2023-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3029607T1 (en) | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| RU2730506C2 (ru) | Твердые формы соединения, модулирующего киназы | |
| JP2023544716A5 (https=) | ||
| JP2022531609A (ja) | 新規メチルキナゾリノン誘導体 | |
| RU2018106453A (ru) | Соединения | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| MX2010012290A (es) | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. | |
| JP2015536986A (ja) | 併用療法 | |
| RU2013154117A (ru) | Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы | |
| JP2017519025A5 (https=) | ||
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| RU2014109747A (ru) | Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor | |
| JP2020117522A (ja) | 徐放性医薬組成物 | |
| JPH11501282A (ja) | コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体 | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль | |
| JP5856264B2 (ja) | ポリエチレングリコール含有組成物 | |
| IL292466B2 (en) | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient | |
| WO2021170811A1 (en) | Method of treating eye disease using trpv4 antagonists | |
| ES3029608T1 (en) | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| TW201726141A (zh) | 嘧啶并嗒酮之治療癌症的用途 | |
| RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
| RU2019111188A (ru) | Кетоновые ингибиторы лизин-специфичного гингипаина | |
| WO2020132636A1 (en) | Analogues of pentamidine and uses therefor | |
| KR20220050956A (ko) | 치료 방법 및 이의 용도 |